Researchers analyzed the ongoing challenges in treating heart failure with reduced ejection fraction (HFrEF) despite advancements in pharmacological and surgical therapies. They emphasized the high morbidity, mortality, and healthcare costs associated with HFrEF and the need for innovative treatments due to the growing heart failure population. They also highlighted left ventricular remodeling and dilatation as a key issue and introduced the concept of minimally invasive, device-based therapies targeting the left ventricle to promote reverse remodeling. Overall, researchers underscored the importance of exploring novel therapeutic approaches to address the challenges posed by HFrEF.
Reference: Spilias N, Howard TM, Anthony CM, et al. Transcatheter left ventriculoplasty. EuroIntervention. 2023 Apr 24;18(17):1399-1407. doi: 10.4244/EIJ-D-22-00544. PMID: 37092265; PMCID: PMC10113960.
